Reneo Pharmaceuticals is a San Diego, CA–based clinical-stage pharmaceutical company focused on therapies for patients with genetic mitochondrial diseases. Its lead investigational candidate, REN001, is an oral, once-daily drug known to control several genes involved in mitochondrial activity. Reneo is developing REN001 as a potential first-in-class treatment to improve cellular energy metabolism by enhancing mitochondrial function and potentially increasing the number of mitochondria. The company announced a $95M Series B financing to advance its clinical development programs. The financing involved both existing and new investors to support continued development of REN001. Reneo also announced the appointment of Gregory J. Flesher as President and CEO, with founding CEO Dr. Niall O’Donnell remaining on the board. Reneo Pharmaceuticals is a San Diego-based clinical stage pharmaceutical company developing therapies for diseases associated with deficits in cellular metabolism and energy production. Its lead program is REN001, a PPAR delta agonist being developed to treat genetically defined rare mitochondrial diseases such as fatty acid oxidation disorders (FAOD) and primary mitochondrial myopathies (PMM). The company is led by president and CEO Niall O'Donnell, Ph.D. Reneo completed a $50m Series A financing to support its programs. Proceeds will fund ongoing Phase 1b clinical trials as well as other clinical and preclinical studies. Its board includes Mike Grey, Niall O'Donnell, Ed Mathers, Johan Kordel, Arthur Pappas and Lon Cardon.

Total raised

$145M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2020